theophylline has been researched along with selegiline in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antonov, L; Atanasov, AG; Hristova, S; Stammler, HG; Tzvetkov, NT | 1 |
| Borges, F; Chavarria, D; Fernandes, C; Gil-Martins, E; Oliveira, PJ; Remião, F; Silva, C; Silva, R; Silva, T; Silva, V; Soares, P | 1 |
| Cabanillas, AM; Coleoni, AH; Masini-Repiso, AM | 1 |
| Müller-Limmroth, W | 1 |
| Musshoff, F | 1 |
| Anttila, M; Karnani, H; Nyman, L; Pelkonen, O; Salonen, JS; Taavitsainen, P | 1 |
| Cody, JT | 1 |
3 review(s) available for theophylline and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine.
Topics: Amphetamines; Animals; Benzphetamine; Furans; Hair; Humans; Methamphetamine; Pyrazoles; Pyrazolones; Selegiline; Sydnones; Theophylline | 2000 |
Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results.
Topics: Amphetamine; Amphetamines; Benzphetamine; Caffeine; Furans; Humans; Methamphetamine; Molecular Structure; Prenylamine; Prodrugs; Pyrazoles; Pyrazolones; Selegiline; Substance Abuse Detection; Sydnones; Theophylline | 2002 |
1 trial(s) available for theophylline and selegiline
| Article | Year |
|---|---|
[The effect of a new antiparkinson agent, Selegilin, on psychomotor performance in humans].
Topics: Adult; Amphetamines; Antiparkinson Agents; Ethylamines; Humans; Male; Phenethylamines; Psychomotor Performance; Reaction Time; Selegiline; Theophylline | 1985 |
13 other study(ies) available for theophylline and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |
(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
Topics: Benzamides; Blood-Brain Barrier; Cerebral Cortex; Models, Neurological; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Permeability; Structure-Activity Relationship | 2019 |
Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
Topics: Alkaloids; Benzodioxoles; Caco-2 Cells; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Rat thyroid monoamine oxidase (MAO) is regulated by thyrotrophin: evidence that the main form of the enzyme (MAO-A) is not directly involved in iodide organification.
Topics: Animals; Bucladesine; Clorgyline; Depression, Chemical; Iodides; Isoenzymes; Male; Methimazole; Monoamine Oxidase; Rats; Rats, Inbred Strains; Selegiline; Theophylline; Thyroid Gland; Thyrotropin; Thyroxine | 1991 |
Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Topics: Amphetamines; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluvoxamine; Humans; Ketoconazole; Methamphetamine; Microsomes, Liver; Mixed Function Oxygenases; Monoamine Oxidase Inhibitors; Selegiline; Theophylline | 2000 |